OGN

Organon & Co.

7 filings tracked

healthcarebiotechnologyLARGE ($10B-200B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

bullishMay 4

Net income surged 68% to $146 million driven by cost reductions and divestitures.

earnings beat

80%

bullishMay 4

Definitive agreement for Sun Pharma to acquire Organon at $14.00 per share.

acquisition

90%

bearishMay 4

Gross profit declined 7% due to unfavorable pricing and product mix.

margin compression

60%

bearishMay 4

Ongoing SEC investigation into Nexplanon sales practices and material internal control weaknesses.

regulatory action

70%

neutralMay 4

Repurchased $419 million of notes to reduce interest expense, though total debt remains high.

debt restructure

40%

Filing History

10-QMay 4, 2026

The Q1 2026 filing presents a company at a critical crossroads, balancing impressive short-term margin expansion against systemic long-term risks. On one hand, Organon has successfully optimized its cost structure and generated record operating cash flow of $225 million, transforming its bottom line through asset divestitures and rigorous expense control. The surge in biosimilar adoption provides a credible path toward sustainable growth, suggesting the business model is evolving toward a more modern, specialized pharmaceutical profile. However, the sustainability of this turnaround is heavily tethered to the successful completion of the Sun Pharma merger. Without this transaction, Organon must confront a daunting debt maturity profile and the operational drag of declining legacy brands. The presence of material weaknesses in internal controls and an active SEC probe adds a layer of regulatory risk that could complicate the merger's closing or impact investor confidence. Ultimately, the filing reveals a company that has cleaned up its balance sheet and trimmed its costs, but still requires a strategic partner to solve its scale and debt challenges.